Wall Street Zen Downgrades Lantheus (NASDAQ:LNTH) to Buy

Lantheus (NASDAQ:LNTH) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

LNTH has been the subject of a number of other reports. Mizuho increased their price target on Lantheus from $72.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, February 27th. Citizens Jmp boosted their price objective on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 24th. William Blair upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday, February 26th. Truist Financial raised their target price on Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Finally, Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Seven research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, Lantheus currently has an average rating of “Moderate Buy” and an average target price of $82.17.

Lantheus Trading Down 1.2%

NASDAQ:LNTH opened at $79.49 on Friday. The firm’s fifty day moving average is $70.53 and its 200-day moving average is $61.79. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70. Lantheus has a 52 week low of $47.25 and a 52 week high of $108.91. The firm has a market cap of $5.17 billion, a P/E ratio of 23.59 and a beta of -0.11.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company had revenue of $406.79 million during the quarter, compared to analysts’ expectations of $367.03 million. During the same period in the prior year, the company posted $1.59 earnings per share. Lantheus’s revenue for the quarter was up 4.0% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts expect that Lantheus will post 6.01 earnings per share for the current year.

Institutional Investors Weigh In On Lantheus

Institutional investors have recently bought and sold shares of the stock. Villanova Investment Management Co LLC bought a new position in Lantheus during the 4th quarter valued at $1,511,000. Alberta Investment Management Corp bought a new stake in shares of Lantheus in the 4th quarter worth $1,617,000. Vident Advisory LLC grew its stake in shares of Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after acquiring an additional 230 shares in the last quarter. Mackenzie Financial Corp raised its holdings in shares of Lantheus by 31.1% in the fourth quarter. Mackenzie Financial Corp now owns 657,674 shares of the medical equipment provider’s stock valued at $44,082,000 after purchasing an additional 156,081 shares during the last quarter. Finally, XTX Topco Ltd raised its holdings in shares of Lantheus by 64.8% in the fourth quarter. XTX Topco Ltd now owns 18,440 shares of the medical equipment provider’s stock valued at $1,227,000 after purchasing an additional 7,252 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.